Retatrutide vs Survodutide
Triple agonist vs GLP-1/glucagon dual.
| Attribute | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) | Survodutide GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Triple-receptor metabolic research | Dual-agonist metabolic research |
| In plain English | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. | Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation. |
| How it works | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. | Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors. |
| Researchers study | Obesity, hepatic steatosis, and metabolic syndrome. | Obesity, NASH/MASH, and metabolic syndrome. |
| Internet discussion | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. | Discussed alongside retatrutide as next-gen weight loss research. |
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.
Survodutide
Dual-agonist metabolic research
Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation.
Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors.
Obesity, NASH/MASH, and metabolic syndrome.
Discussed alongside retatrutide as next-gen weight loss research.
Survodutide is a dual GLP-1/Glucagon agonist researched for weight and liver outcomes.